Chang-wei-qing, a Chinese herbal formula, ameliorates colitis-associated tumour development via inhibiting NF-κB and STAT3 signalling pathway

References

• Ahmed S, Johnson K, Ahmed O, Iqbal N. 2014. Advances in the management of colorectal cancer: from biology to treatment. Int J Colorect Dis. 29:1031–1042.
   PubMed Web of Science ®Google Scholar
• Candela M, Turroni S, Biagi E, Carbonero F, Rampelli S, Fiorentini C, Brigidi P. 2014. Inflammation and colorectal cancer, when microbiota-host mutualism breaks. World J Gastroenterol. 20:908–922.
   PubMed Web of Science ®Google Scholar
• Cheng KW, Tseng CH, Tzeng CC, Leu YL, Cheng TC, Wang JY, Chang JM, Lu YC, Cheng CM, Chen IJ. 2018. Pharmacological inhibition of bacterial beta-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo. Pharmacol Res. 1:41–49.
   Google Scholar
• El-Khadragy MF, Nabil HM, Hassan BN, Tohamy AA, Waaer HF, Yehia HM, Alharbi AM, Moneim AEA. 2018. Bone marrow cell therapy on 1,2-dimethylhydrazine (DMH)-induced colon cancer in rats. Cell Physiol Biochem. 45:1072–1083.
   PubMed Web of Science ®Google Scholar
• Feng S, Song J. 1999. Relationship of beta-glucuronidase to differentiation and invasion of human colorectal carcinoma. Chin Med J. 112:854–857.
   PubMed Web of Science ®Google Scholar
• Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, et al. 2009. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 15:103–113.
   PubMed Web of Science ®Google Scholar
• Han J, Theiss AL. 2014. Stat3: friend or foe in colitis and colitis-associated cancer? Inflamm Bowel Dis. 20:2405–2411.
   PubMed Web of Science ®Google Scholar
• Kawee-Ai A, Kim SM. 2014. Application of microalgal fucoxanthin for the reduction of colon cancer risk: inhibitory activity of fucoxanthin against beta-glucuronidase and DLD-1 cancer cells. Nat Prod Commun. 9:921–924.
   PubMed Web of Science ®Google Scholar
• Kim ER, Chang DK. 2014. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. World J Gastroenterol. 20:9872–9881.
   PubMed Web of Science ®Google Scholar
• Klimesova K, Kverka M, Zakostelska Z, Hudcovic T, Hrncir T, Stepankova R, Rossmann P, Ridl J, Kostovcik M, Mrazek J, et al. 2013. Altered gut microbiota promotes colitis-associated cancer in IL-1 receptor-associated kinase M-deficient mice. Inflamm Bowel Dis. 19:1266–1277.
   PubMed Web of Science ®Google Scholar
• Li J, Fan ZZ, Sun J, Xu JH. 2011. In vitro antimetastatic effect of Changweiqing through antiinvasion of hypoxic colorectal carcinoma LoVo cells. Chin J Integr Med. 17:517–524.
   PubMed Web of Science ®Google Scholar
• Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C, Lin J. 2011. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res. 71:7226–7237.
   PubMed Web of Science ®Google Scholar
• Markowitz SD, Bertagnolli MM. 2009. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 361:2449–2460.
   PubMed Web of Science ®Google Scholar
• Moossavi S, Bishehsari F. 2012. Inflammation in sporadic colorectal cancer. Arch Iran Med. 15:166–170.
   PubMed Web of Science ®Google Scholar
• Nagy N, Bronckart Y, Camby I, Legendre H, Lahm H, Kaltner H, Hadari Y, Van Ham P, Yeaton P, Pector JC, et al. 2002. Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut. 50:392–401.
   PubMed Web of Science ®Google Scholar
• Peeters PJ, Bazelier MT, Leufkens HG, de Vries F, De Bruin ML. 2015. The risk of colorectal cancer in patients with type 2 diabetes: associations with treatment stage and obesity. Diabetes Care. 38:495–502.
   PubMed Web of Science ®Google Scholar
• Reynoso-Camacho R, Guerrero-Villanueva G, Figueroa JdD, Gallegos-Corona MA, Mendoza S, Loarca-Piña G, Ramos-Gomez M. 2015. Anticarcinogenic effect of corn tortilla against 1,2-dimethylhydrazine (DMH)-induced colon carcinogenesis in Sprague-Dawley rats. Plant Foods Hum Nutr (Dordrecht, Netherlands). 70:146–152.
   PubMed Web of Science ®Google Scholar
• Sheflin AM, Whitney AK, Weir TL. 2014. Cancer-promoting effects of microbial dysbiosis. Curr Oncol Rep. 16:406–414.
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. 2013. Cancer statistics, 2013. CA: Cancer J Clin. 63:11–30.
   PubMed Web of Science ®Google Scholar
• Simon K. 2016. Colorectal cancer development and advances in screening. Clin Interv Aging. 11:967–976.
   PubMed Web of Science ®Google Scholar
• Sobhani I, Tap J, Roudot-Thoraval F, Roperch JP, Letulle S, Langella P, Corthier G, Tran Van Nhieu J, Furet JP. 2011. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One. 6:e16393.
   PubMed Web of Science ®Google Scholar
• Spitzner M, Roesler B, Bielfeld C, Emons G, Gaedcke J, Wolff HA, Rave-Fränk M, Kramer F, Beissbarth T, Kitz J, et al. 2014. STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo. Int J Cancer. 134:997–1007.
   PubMed Web of Science ®Google Scholar
• Summart R, Chewonarin T. 2014. Purple rice extract supplemented diet reduces DMH- induced aberrant crypt foci in the rat colon by inhibition of bacterial β-glucuronidase. Asian Pac J Cancer Prev. 15:749–755.
   PubMedGoogle Scholar
• Sun Y, Li Y. 1988. Induction of beta-glucuronidase activity during dimethylhydrazine carcinogenesis and additive effects of cholic acid and indole. Cancer Lett. 39:69–76.
   PubMed Web of Science ®Google Scholar
• Waszkiewicz N, Szajda SD, Konarzewska-Duchnowska E, Zalewska-Szajda B, Gałązkowski R, Sawko A, Nammous H, Buko V, Szulc A, Zwierz K, et al. 2015. Serum β-glucuronidase as a potential colon cancer marker: a preliminary study. Postepy Higieny i Medycyny Doswiadczalnej (Online). 69:436–439.
   PubMedGoogle Scholar
• Xu JH, Deng WL, Fan ZZ. 2010. Effects of changwelqing on nuclear translocation of Y-box binding protein-1 and expression of P-glycoprotein in human colon cancer cell line with drug-resistance induced by vincristine. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi = Chin J Integr Trad West Med. 30:743–747.
   PubMedGoogle Scholar
• Zhang Y, Sun XW, Xu JH, Lu H, Fan ZZ, Sun J, Zhang XX. 2012. Effects of medicated serum prepared with Chinese herbal medicine Changweiqing on pharmacokinetics of oxaliplatin in colon cancer cells. Zhong Xi Yi Jie He Xue Bao = J Chin Integr Med. 10:901–910.
   PubMedGoogle Scholar
• Zhang Y, Zhang Q, Fan Z, Sun J, Liu X, Cheng L, Li A, Xu J. 2015. A Chinese herbal formula, Chang-Wei-Qin, synergistically enhances antitumor effect of oxaliplatin. Pathol Oncol Res. 21:389–397.
   PubMed Web of Science ®Google Scholar